Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH27012D
  • |
  • Pages: 69
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasticity; and neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc (ACOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For USD 13 Million 13

Venture Financing 15

Civitas Therapeutics Raises USD55 Million in Series C Financing 15

Civitas Therapeutics Raises USD 38 Million In Series B Venture Financing 17

Private Equity 19

Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19

Partnerships 20

Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21

Licensing Agreements 22

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22

Equity Offering 23

Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23

Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24

Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25

Civitas Therapeutics Withdraw IPO for up to USD80 million 27

Biotie Therapies Completes Private Placement Of Shares For USD 25 Million 28

Debt Offering 29

Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29

Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31

Asset Transactions 33

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33

Acquisition 34

Biogen and UCB May Acquire Acorda Therapeutics 34

Acorda Therapeutics Rejects Plan of its Sale 35

Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36

Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 39

Acorda Therapeutics Inc-Key Competitors 40

Acorda Therapeutics Inc-Key Employees 41

Acorda Therapeutics Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 44

Strategy And Business Planning 44

Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44

Financial Announcements 45

Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45

Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47

May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48

Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50

Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52

Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54

Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56

Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58

Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60

Corporate Communications 62

Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62

Product News 63

04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63

Clinical Trials 64

Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64

Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65

Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67

Appendix 69

Methodology 69

About GlobalData 69

Contact Us 69

Disclaimer 69

List of Figures

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For USD 13 Million 13

Civitas Therapeutics Raises USD55 Million in Series C Financing 15

Civitas Therapeutics Raises USD 38 Million In Series B Venture Financing 17

Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19

Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20

Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21

H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22

Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23

Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24

Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25

Civitas Therapeutics Withdraw IPO for up to USD80 million 27

Biotie Therapies Completes Private Placement Of Shares For USD 25 Million 28

Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29

Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31

Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33

Biogen and UCB May Acquire Acorda Therapeutics 34

Acorda Therapeutics Rejects Plan of its Sale 35

Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36

Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38

Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 39

Acorda Therapeutics Inc, Key Competitors 40

Acorda Therapeutics Inc, Key Employees 41

Acorda Therapeutics Inc, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acorda Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17798
Site License
USD 500 INR 35595
Corporate User License
USD 750 INR 53393

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com